Alexandre López-Gavín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexandre López-Gavín has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Vergara
Microbiology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain; Institute of Global Health (ISGlobal), Barcelona, Spain; CIBERINFEC, CIBER in Infectious Diseases, ISCIII, Madrid, Spain; University of Barcelona, Faculty of Medicine, Barcelona, Spain
3 shared publications - Juan Carlos Hurtado
Barcelona Institute for Global Health (ISGlobal), Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain
3 shared publications - Julià González-Martín
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona-ISGlobal, Universitat de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
3 shared publications - Griselda Tudó
Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain
2 shared publications Anne D. Villela
Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF) and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga 6681 - Prédio 92A Tecnopuc, 90619-900 Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Porto Alegre, Brazil
1 shared publication- Bruno Lopes Abbadi
Department of Biochemistry and Molecular Biology, Rutgers-Robert Wood Johnson Medical School
1 shared publication
Latest Publications
- 1 January 2016
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 47 (1) , 97-100
In vitro time–kill curves study of three antituberculous combinations against Mycobacterium tuberculosis clinical isolates
- 1 January 2016
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 47 (1) , 97-100
In vitro time–kill curves study of three antituberculous combinations against Mycobacterium tuberculosis clinical isolates
- 1 November 2015
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 46 (5) , 582-585
In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid
- 1 November 2015
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 46 (5) , 582-585
In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid
- 26 April 2015
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 34 (8) , 1527-1532
Implementation of MALDI-TOF MS technology for the identification of clinical isolates of Mycobacterium spp. in mycobacterial diagnosis
A total of 243 clinical isolates of the Mycobacterium genus were studied, 143 and 100 using two protocols (Protocol v2 and Protocol v3, respectively) provided by the manufacturer. The overall correlation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with the standard identification methods was 63.8 %. The rate of misidentification was 3.2 %, mainly affecting very close species. In Protocol v2, the correlation was 57.3 %, being greater in solid than in liquid media (71.7 % vs. 44.7 %, p < 0.05). Albeit not significant, a trend to a greater correlation for M. tuberculosis complex compared to non-tuberculous mycobacteria (NTM) (63.6 % vs. 55.5 %) was observed. In Protocol v3, the correlation was 73 %, with no significant differences between solid and liquid media (70.8 % vs. 75 %). In conclusion, MALDI-TOF MS may play a role in identifying mycobacterial species isolated from clinical samples, being faster than sequencing and hybridization-based techniques.
- 26 April 2015
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 34 (8) , 1527-1532
Implementation of MALDI-TOF MS technology for the identification of clinical isolates of Mycobacterium spp. in mycobacterial diagnosis
A total of 243 clinical isolates of the Mycobacterium genus were studied, 143 and 100 using two protocols (Protocol v2 and Protocol v3, respectively) provided by the manufacturer. The overall correlation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with the standard identification methods was 63.8 %. The rate of misidentification was 3.2 %, mainly affecting very close species. In Protocol v2, the correlation was 57.3 %, being greater in solid than in liquid media (71.7 % vs. 44.7 %, p < 0.05). Albeit not significant, a trend to a greater correlation for M. tuberculosis complex compared to non-tuberculous mycobacteria (NTM) (63.6 % vs. 55.5 %) was observed. In Protocol v3, the correlation was 73 %, with no significant differences between solid and liquid media (70.8 % vs. 75 %). In conclusion, MALDI-TOF MS may play a role in identifying mycobacterial species isolated from clinical samples, being faster than sequencing and hybridization-based techniques.